Illumina Acquires SomaLogic to Extend Platform into Proteomics
SHERIDAN, WYOMING - April 14, 2026 - Illumina has announced the acquisition of SomaLogic, describing the deal as a unification that will deliver a powerful portfolio of proteomics solutions. The move extends Illumina's core sequencing and array business into protein-level biology, a domain increasingly central to translational research, drug discovery, and clinical diagnostics. Combined with Illumina's existing NGS-based proteomics services offered through the Illumina Protein Prep solution, the acquisition adds significant depth to the company's multiomics ambitions. For laboratory operators and life science research institutions, the deal raises the prospect of sourcing genomic and proteomic workflows from a single integrated vendor.